Drugs target 4 aberrant pathways implicated in the development of PAH: Endothelin pathway Nitric oxide pathway Prostacyclin pathway BMPR2 pathway The endothelin pathway is targeted by bosentan, ambrisentan, and macitentan, which are oral endothelin-receptor antagonists (ERAs).